11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations

11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations

Introduction to the Cutaneous Lupus Spectrum

Lupus erythematosus (LE) represents an autoimmune disease spectrum spanning localized, organ-specific cutaneous disease to life-threatening multisystemic inflammation. In dermatovenereological practice, distinguishing between cutaneous lupus erythematosus (CLE) subtypes, identifying cutaneous markers of visceral involvement (particularly lupus nephritis), interpreting serological autoantibody profiles, and executing evidence-based management protocols form core specialist competencies.

The global classification of cutaneous manifestations rests on the Gilliam Classification of Lupus Erythematosus, which separates skin findings into LE-specific skin disease (histologically defined by interface dermatitis) and LE-nonspecific skin disease (vascular, follicular, or connective tissue signs lacking interface dermatitis, frequently mirroring systemic disease activity).

                                    ┌────────────────────────────────────────────────────────┐
                                    │             Gilliam Classification of LE               │
                                    └───────────────────────────┬────────────────────────────┘
                                                                │
                                ┌───────────────────────────────┴───────────────────────────────┐
                                │                                                               │
                ┌───────────────▼───────────────┐                               ┌───────────────▼───────────────┐
                │      LE-Specific Lesions      │                               │     LE-Nonspecific Lesions    │
                │     (Interface Dermatitis)    │                               │   (Lacks Interface Changes)   │
                └───────────────┬───────────────┘                               └───────────────┬───────────────┘
                                │                                                               │
        ┌───────────────────────┼───────────────────────┐                                       ├─ Raynaud phenomenon
        │                       │                       │                                       ├─ Livedo reticularis / racemosa
┌───────▼───────┐       ┌───────▼───────┐       ┌───────▼───────┐                               ├─ Periungual telangiectasia
│   Acute CLE   │       │  Subacute CLE │       │  Chronic CLE  │                               ├─ Non-scarring alopecia ("lupus hair")
│    (ACLE)     │       │    (SCLE)     │       │    (CCLE)     │                               ├─ Bullous SLE (anti-type VII collagen)
└───────┬───────┘       └───────┬───────┘       └───────┬───────┘                               └─ Calcinosis cutis / urticarial vasculitis
        │                       │                       │
        ├─ Malar rash           ├─ Annular-polycyclic   ├─ Classical Discoid LE (localized / generalized)
        ├─ Generalized maculo-  └─ Papulosquamous       ├─ Lupus Panniculitis / Profundus
        │  papular LE              (psoriasiform)       ├─ Chilblain Lupus
        └─ TEN-like ACLE                                └─ Lupus Tumidus (LET)

---

Gilliam Classification: LE-Specific Manifestations

1. Acute Cutaneous Lupus Erythematosus (ACLE)

ACLE is virtually synonymous with active systemic disease; greater than 90% of ACLE patients fulfill ACR/EULAR classification criteria for Systemic Lupus Erythematosus (SLE).

• Localized ACLE (Malar / Butterfly Rash): Erythema and edema symmetrically distributed across the malar eminences and the bridge of the nose. A cardinal diagnostic discriminator is the conspicuous sparing of the nasolabial folds (in contrast to seborrhoeic dermatitis, rosacea, or erysipelas, which characteristically involve the nasolabial folds). The eruption is non-scarring, highly photosensitive, and fluctuates rapidly with systemic disease flares.
• Generalized ACLE (Maculopapular / Exanthematous LE): Widespread, diffuse, symmetric, pruritic or burning morbilliform/maculopapular eruption, typically photodistributed across the forehead, extensor upper extremities, and "V-neck" distribution, sparing the knuckles (interphalangeal skin) or involving the interarticular skin while sparing the joints (distinguishing ACLE from dermatomyositis).
• Toxic Epidermal Necrolysis-like ACLE (TEN-like ACLE): A severe, life-threatening variant presenting with diffuse, full-thickness epidermal necrolysis, widespread blistering, and cutaneous denudation arising in patients with hyperacute, active SLE. Differentiating TEN-like ACLE from medication-induced Stevens-Johnson syndrome / toxic epidermal necrolysis (SJS/TEN) is a high-yield exam conundrum:
  • TEN-like ACLE: Pre-existing or concurrent multiorgan SLE flare, severe active lupus nephritis, positive anti-Ro/SSA, anti-dsDNA, high-titer ANA, granular dermo-epidermal junction deposits on direct immunofluorescence (DIF), and favorable response to high-dose corticosteroids/intravenous immunoglobulins.
  • Medication-induced SJS/TEN: Distinct drug exposure window (1–4 weeks), prominent mucosal sloughing (>=2 mucosal sites), negative ANA/dsDNA, negative DIF.

2. Subacute Cutaneous Lupus Erythematosus (SCLE)

SCLE represents a distinct clinical and immunogenetic subset characterized by extreme UV photosensitivity, non-scarring superficial cutaneous plaques, strong association with HLA-DR3, and circulating anti-Ro/SSA autoantibodies in >80% of patients.

• Approximately 50% of SCLE patients fulfill SLE criteria, but severe renal or central nervous system involvement is relatively infrequent (~10–15%); mild arthralgias, fatigue, and serositis predominate.
• Morphologic Variants:
  1. Annular-Polycyclic SCLE: Erythematous, slightly raised annular lesions with central clearing, peripheral expanding active erythematous borders, and fine collarettes of scale. Lesions coalesce into polycyclic or gyrate arrays.
  2. Papulosquamous (Psoriasiform) SCLE: Discrete, erythematous papules and plaques covered with fine, non-adherent scale, closely mimicking psoriasis or pityriasis rosea, but strictly photodistributed.
• Healing Dynamics: SCLE does not cause follicular plugging, induration, or scarring. However, it frequently resolves with striking, persistent vitiligo-like post-inflammatory hypopigmentation and telangiectasia.
• Drug-Induced SCLE (DI-SCLE): Up to 30% to 40% of all SCLE presentations are drug-induced. Clinically and serologically, DI-SCLE is indistinguishable from idiopathic SCLE (presenting with identical annular/papulosquamous plaques and positive anti-Ro/SSA). The latency period ranges from weeks to several years. European pharmacovigilance highlights the following core pharmacological culprits:
  • Antifungals: Terbinafine (highest relative risk).
  • Antihypertensives / Diuretics: Hydrochlorothiazide (HCTZ), calcium channel blockers (diltiazem, nifedipine), ACE inhibitors.
  • Gastrointestinal Agents: Proton pump inhibitors (omeprazole, pantoprazole, esomeprazole).
  • Biologics & Targeted Drugs: Anti-TNF agents (etanercept, infliximab, adalimumab), immune checkpoint inhibitors (anti-PD-1 / anti-PD-L1).
  • Chemotherapeutics / Anticonvulsants: Fluorouracil, docetaxel, carbamazepine.
  • Management: Offending drug withdrawal is paramount; resolution generally occurs within 4 to 12 weeks, though antibody titers may persist for months.

3. Chronic Cutaneous Lupus Erythematosus (CCLE)

CCLE lesions are characterized by prominent structural alterations, dermal infiltration, and high propensity for permanent scarring.

Classical Discoid Lupus Erythematosus (DLE)

DLE is the most prevalent form of CCLE. Progression to systemic SLE occurs in only 5% of localized DLE, but rises to 15% to 20% in generalized DLE (lesions both above and below the neck).

• Clinical Diagnostic Triad:
  1. Follicular Plugging & Adherent Hyperkeratotic Scale: When the adherent scale is peeled back, keratotic spikes protruding from the undersurface into patulous follicular orifices are visible—the pathognomonic "carpet tack" sign (tapieziernagel-phänomen or cat's tongue sign).
  2. Active Peripheral Border: Indurated, erythematous to violaceous, hyperpigmented border reflecting ongoing interface inflammation.
  3. Central Cicatricial Atrophy: Burnt-out central area demonstrating permanent dermal thinning, depigmentation, telangiectasia, and destruction of adnexal structures.
• Scalp Involvement: Produces scarring, permanent cicatricial alopecia with follicular drop-out and permanent loss of ostia. Dermoscopy displays white fibrotic areas, follicular keratotic plugs, branching red lines, and peri-infundibular hyperpigmentation.
• Malignancy Risk (Squamous Cell Carcinoma in DLE): Long-standing, chronic hypertrophic or scarred discoid lesions—especially on the lower lip (lupus cheilitis), scalp, and ears—harbor a 3% to 5% lifetime risk of malignant transformation into aggressive Cutaneous Squamous Cell Carcinoma (cSCC). Any non-healing ulceration, verrucous nodule, or rapidly enlarging vegetation within a chronic discoid scar requires immediate biopsy.

Lupus Erythematosus Panniculitis / Profundus

• Characterized by deep, firm, tender, movable subcutaneous nodules and plaques located predominantly on the proximal upper arms, shoulders, buttocks, thighs, breasts, and face.
• The overlying skin may be normal or exhibit classical discoid changes (Lupus Profundus).
• Lesions heal with permanent, disfiguring lipodystrophic saucer-like depressions (lipoatrophy).
• Histopathology reveals a lobular lymphocytic panniculitis, hyaline fat necrosis, lymphoid follicles, and heavy mucin deposition.

Chilblain Lupus Erythematosus

• Perniotic, dusky-violaceous, pruritic or painful papules and plaques triggered by damp, cold environments, localized to acral surfaces: dorsal fingers, toes, heels, nose, and ear helices.
• Differentiated from idiopathic perniosis/chilblains by persistence into warm spring/summer months, female predominance, presence of autoantibodies (ANA, Ro/SSA, hypergammaglobulinemia), and positive dermo-epidermal immunoglobulin deposition on DIF.
• Monogenic familial chilblain lupus is linked to autosomal dominant mutations in TREX1 or SAMHD1, resulting in intracellular nucleic acid accumulation and constitutive Type I interferon overexpression.

Lupus Erythematosus Tumidus (LET)

• Manifests as juicy, succulent, single or multiple, smooth-surfaced, erythematous-to-violaceous urticarial plaques without epidermal involvement (strictly no follicular plugging, no scale, no atrophy, no scarring).
• Distribution: Prominently photodistributed across the face, upper trunk, and shoulders.
• Characterized by extreme photosensitivity with a pronounced delayed onset following UV exposure (often days to weeks).
• Direct immunofluorescence is typically negative (or shows only faint, fragmented IgM).
• Carries an exceptional prognosis: virtually zero progression to systemic SLE and demonstrates dramatic responsiveness to systemic antimalarials.

---

LE-Nonspecific Cutaneous Manifestations

LE-nonspecific lesions represent cutaneous expressions of circulating immune complexes, vasculopathy, hypercoagulability, or systemic inflammation lacking lichenoid interface dermatitis:

1. Vascular Phenomena:
   • Raynaud Phenomenon: Triphasic color changes (pallor/white -> cyanosis/blue -> rubor/reactive erythema); present in 30–50% of SLE patients.
   • Livedo Reticularis / Racemosa: Violaceous, reticulated vascular patterning. Irregular, broken, asymmetric rings (livedo racemosa) strongly indicate underlying antiphospholipid syndrome (APS) and microvascular thrombosis.
   • Periungual Telangiectasia: Dilated capillary loops and cuticular erythema with micro-petechiae.
   • Palpable Purpura & Urticarial Vasculitis: Reflecting leukocytoclastic small-vessel vasculitis.
2. Alopecia Patterns:
   • Lupus Hair: Dry, lusterless, brittle hairs along the frontal hairline that fragment easily, producing a disheveled appearance.
   • Non-scarring Diffuse Telogen Effluvium: Correlates directly with active systemic SLE flares, resolving upon disease control.
   • Discoid Cicatricial Alopecia: Permanent scarring alopecia with complete loss of follicular orifices (LE-specific).
3. Bullous Systemic Lupus Erythematosus (BSLE):
   • A rare, non-scarring autoimmune blistering manifestation occurring exclusively in patients with active systemic SLE.
   • Presents with widespread, tense subepidermal vesicles, bullae, and urticarial plaques on both sun-exposed and covered skin.
   • Pathophysiology: Mediated by circulating autoantibodies against Type VII collagen (the structural anchoring fibril component of the dermo-epidermal junction, identical to epidermolysis bullosa acquisita).
   • Histology & DIF: Subepidermal blister with dense neutrophilic microabscesses within the dermal papillae; DIF shows continuous granular-to-linear IgG, IgM, and C3 along the dermo-epidermal junction.
   • Therapeutic Pearl: Demonstrates rapid, dramatic responsiveness to oral dapsone (50–150 mg/day).
4. Mucosal & Soft Tissue Lesions:
   • Painless palatal and oral ulcerations (a recognized diagnostic criterion for SLE).
   • Calcinosis cutis, rheumatoid-like nodules, and Degos-like atrophic porcelain papules.

---

Comprehensive CLE Subtype Diagnostic Comparison

---

Dermatopathology and Immunofluorescence

                                    ┌────────────────────────────────────────────────────────┐
                                    │             Cutaneous LE Histopathology                │
                                    └───────────────────────────┬────────────────────────────┘
                                                                │
                ┌───────────────────────────────────────────────┴───────────────────────────────────────────────┐
                │                                                                                               │
┌───────────────▼───────────────┐                                                               ┌───────────────▼───────────────┐
│      Epidermal Changes        │                                                               │        Dermal Changes         │
└───────────────┬───────────────┘                                                               └───────────────┬───────────────┘
                │                                                                                               │
                ├─ Hyperkeratosis with follicular plugging (DLE)                                                ├─ Thickened basement membrane (PAS+)
                ├─ Epidermal atrophy (variable)                                                                 ├─ Interface vacuolar degeneration
                ├─ Basal layer vacuolar alteration                                                              ├─ Abundant interstitial mucin (Alcian blue)
                └─ Apoptotic keratinocytes (colloid / Civatte bodies)                                           ├─ Perivascular & periadnexal lymphocytic infiltrate
                                                                                                                └─ Extravasated erythrocytes & dermal edema

Classic Histopathologic Pattern

The histological signature across the LE-specific spectrum is an interface dermatitis (vacuolar reaction type):

1. Basal Vacuolar Degeneration: Hydropic swelling and vacuolization of the basal keratinocyte layer, leading to blurring of the dermo-epidermal junction.
2. Keratinocyte Apoptosis: Eosinophilic, shrunken, apoptotic basal cells referred to as colloid bodies, Civatte bodies, or cytoid bodies.
3. Basement Membrane Zone (BMZ) Thickening: Striking accumulation of degraded basement membrane components, demonstrated prominently by Periodic acid–Schiff (PAS) staining.
4. Perivascular & Periadnexal Infiltration: Dense, coat-sleeve lymphocytic infiltrate (predominantly CD4+ and CD8+ T cells alongside plasmacytoid dendritic cells) distributed around superficial and deep vascular plexuses, hair follicles, and eccrine coils.
5. Dermal Mucin Deposition: Marked accumulation of glycosaminoglycans and interstitial mucin separating collagen bundles in the reticular dermis, selectively highlighted using Alcian blue (pH 2.5) or colloidal iron stains.

The Lupus Band Test (LBT)

The Lupus Band Test refers to direct immunofluorescence (DIF) microscopy demonstrating a continuous, granular, or shaggy band of immunoreactants—principally IgG, IgM, and complement component C3 (± IgA, C1q)—deposited along the dermo-epidermal junction.

• Biopsy Handling: DIF requires fresh, unfixated tissue transported in Michel's holding medium or placed on saline-moistened gauze for immediate cryosectioning; formalin fixation permanently destroys tissue immunoreactivity.
• Diagnostic Interpretation Rules:
  • Lesional Skin: Positive in >90% of CCLE/DLE and ACLE, and ~60% of SCLE. Proves an immune-complex mediated interface dermatitis.
  • Clinically Normal, Sun-Exposed Skin (e.g., extensor forearm): Positive in 70% to 80% of patients with active systemic SLE.
  • Clinically Normal, Sun-Protected Skin (e.g., medial upper arm, buttock): The Gold Standard LBT. A positive continuous granular band in normal, sun-protected skin is highly specific for active, severe Systemic Lupus Erythematosus. It correlates directly with elevated anti-dsDNA antibodies, serum hypocomplementemia (low C3/C4), and a high statistical probability of active proliferative lupus nephritis (ISN/RPS Class III or IV).

---

Autoantibody Biomarkers in Lupus

Neonatal Lupus Erythematosus (NLE) & Congenital Heart Block

Neonatal lupus is a passively acquired autoimmune syndrome caused by the transplacental transfer of maternal IgG autoantibodies against Ro/SSA (especially anti-Ro52) and La/SSB across the syncytiotrophoblast beginning at gestational week 16.

• Cutaneous Manifestations: Develop within the first few weeks of life, often triggered by UV phototherapy for neonatal jaundice. Manifests as annular, erythematous, non-scarring plaques with fine scale, classically displaying periorbital erythema ("raccoon eyes" or "owl-eye" appearance). Lesions spontaneously resolve within 6 to 8 months as maternal IgG antibodies are cleared from the infant's circulation.
• Congenital Heart Block (CHB): The most devastating consequence. Anti-Ro52 antibodies bind to L-type calcium channels on fetal cardiomyocytes, inducing autoimmune myocarditis, calcification, and irreversible destruction of the atrioventricular (AV) node between gestational weeks 18 and 24.
  • Results in permanent third-degree (complete) congenital heart block in 1% to 2% of mothers with anti-Ro/SSA antibodies (risk escalates to 15% to 20% in subsequent pregnancies following an affected child).
  • Unlike cutaneous NLE, congenital heart block is irreversible and requires permanent pacemaker implantation in >80% of affected neonates.
  • Maternal Surveillance: Serial fetal Doppler echocardiography weekly from week 16 to week 26; prophylactic maternal hydroxychloroquine reduces the recurrence risk by >50%.

---

European Management Guidelines for Cutaneous Lupus

European management of CLE follows the standardized consensus recommendations of the European Dermatology Forum (EDF) and the European Academy of Dermatology and Venereology (EADV).

1. General Measures & Photoprotection

• Broad-Spectrum Photoprotection: Strict compliance with daily broad-spectrum sunscreens protecting against both UVB (SPF >= 50+) and UVA (high UVA-PF / PPD >= 20) containing physical blockers (titanium dioxide, zinc oxide) and stable chemical filters. Patients must apply sunscreen 20 minutes prior to outdoor exposure and reapply every 2 hours.
• UV-Protective Lifestyle: Wide-brimmed hats, dense woven fabrics, UV-protective window tinting for vehicles/homes, and avoidance of midday UV peaks (11:00–15:00).
• Smoking Cessation: Smoking is associated with more active and more extensive cutaneous lupus. In observational studies and meta-analysis, smokers are less likely to respond to hydroxychloroquine and chloroquine; the mechanism is uncertain. Every smoker with CLE should be offered cessation support.
• Vitamin D Supplementation: Due to strict photoprotection, baseline serum 25-hydroxyvitamin D must be checked and supplemented (typically 800–2,000 IU daily).

2. Topical & Intralesional Therapy

• Topical Corticosteroids (TCS):
  • Trunk, Extremities & Scalp DLE: High-potency to superpotent corticosteroids (European Class III/IV, e.g., clobetasol propionate 0.05%, betamethasone dipropionate 0.05%) applied once daily for 2 to 4 weeks, tapering to alternate-day or weekend maintenance to control active indurated borders.
  • Face & Intertriginous Areas: Moderate-potency corticosteroids (European Class II, e.g., hydrocortisone butyrate 0.1%, aclometasone dipropionate 0.05%) restricted to short courses (<=2 weeks) to avoid steroid-induced atrophy, telangiectasia, and perioral dermatitis.
• Topical Calcineurin Inhibitors (TCIs):
  • Tacrolimus 0.1% ointment and Pimecrolimus 1% cream represent first-line steroid-sparing topical agents, particularly for facial ACLE, SCLE, and sensitive intertriginous/eyelid skin. They inhibit calcineurin-dependent NFAT translocation without inducing dermal atrophy, glaucoma, or telangiectasia.
• Intralesional Corticosteroids:
  • Triamcinolone acetonide (2.5 to 10 mg/mL) injected intralesionally into the active hyperkeratotic borders of refractory discoid plaques or scalp cicatricial lesions.

3. Systemic Antimalarial Therapy (First-Line Anchor)

Systemic antimalarials are the foundational anchor of all CLE and SLE management, providing photoprotective, anti-inflammatory, immunomodulatory, and antithrombotic effects while reducing disease mortality.

Hydroxychloroquine (HCQ)

• Standard Dosing: Dosed strictly according to actual body weight up to a maximum of 5.0 mg/kg/day (typically 200–400 mg daily). Historical guidelines based on "ideal body weight" have been abandoned by European and ophthalmological societies because actual weight calculations prevent accidental overdosing in thin or elderly individuals.
• Onset of Action: Antimalarials require 8 to 12 weeks to achieve therapeutic tissue equilibrium; clinical efficacy should not be judged premature to 3 months of compliant dosing.

Antimalarial Retinopathy & Mandatory Ophthalmology Surveillance

Antimalarials bind to melanin in the retinal pigment epithelium (RPE), leading to lysosomal inhibition, photoreceptor degeneration, and classic bilateral "bull's-eye" maculopathy (a ring of RPE depigmentation sparing the foveal center). Advanced retinopathy is permanent and can progress even after medication cessation.

• European Consensus Screening Protocol:
  1. Baseline Examination: Comprehensive ophthalmological assessment within the first year of starting HCQ.
  2. Annual Screening: Initiated after 5 years of continuous therapy for patients without major risk factors.
  3. High-Risk Patients (Screening initiated earlier / annually from Year 1):
     • Daily dose exceeding >5.0 mg/kg actual body weight.
     • Chronic kidney disease (estimated GFR < 60 mL/min/1.73m²), which delays drug elimination.
     • Concomitant use of tamoxifen (which increases retinopathy risk up to 5-fold due to metabolic synergy).
     • Pre-existing macular or retinal disease.
  4. Screening Modalities: Subjective funduscopic examination alone is deemed insufficient. Contemporary European screening mandates objective imaging:
     • Spectral-Domain Optical Coherence Tomography (SD-OCT): Detects early thinning of the parafoveal photoreceptor inner segment/outer segment junction (the pathognomonic "flying saucer" sign).
     • Automated Visual Field (Humphrey 10-2 testing): Parafoveal scotomas in Caucasian populations; wider 24-2 or 30-2 fields are required in Asian populations due to a recognized predilection for pericentral/peripheral retinal toxicity.

Combination Antimalarial Regimens

• Quinacrine (Mepacrine): In patients with incomplete response to HCQ monotherapy, adding quinacrine at 100 mg daily produces synergistic clinical clearance. Quinacrine is not retinotoxic, eliminating cumulative retinal burden. Adverse effects include reversible lemon-yellow discoloration of the skin, sclera, and bodily fluids, and rarely bone marrow aplasia.
• Chloroquine Phosphate: Alternative to HCQ (dosed <=2.3 mg/kg actual body weight/day), but carries a significantly higher risk of retinal toxicity compared to HCQ.

4. Second-Line & Third-Line Systemic Therapies

For antimalarial-refractory CLE, severe generalized DLE, or multiorgan SLE involvement:

• Methotrexate (MTX): 15 to 25 mg weekly (subcutaneous or oral) plus folic acid; highly effective for generalized DLE and SCLE.
• Mycophenolate Mofetil (MMF): 2.0 to 3.0 g daily; inhibits inosine monophosphate dehydrogenase; superior safety profile and exceptional efficacy for refractory CLE and lupus nephritis.
• Dapsone: 50 to 150 mg daily (check G6PD activity prior to initiation); therapy of choice for Bullous SLE and highly effective in lupus tumidus.
• Systemic Retinoids: Acitretin (10–25 mg daily) or isotretinoin; useful for hyperkeratotic, verrucous DLE plaques, adhering to strict teratogenicity pregnancy prevention programs.

5. Targeted Biologic Therapies

• Belimumab: Fully human IgG1-lambda monoclonal antibody that selectively binds and neutralizes soluble B-lymphocyte stimulator (BLyS / BAFF), blocking B-cell differentiation and survival. Approved in the EU as add-on therapy for active, autoantibody-positive SLE with high disease activity despite standard therapy (and for lupus nephritis); the label does not specify cutaneous involvement.
• Anifrolumab: Breakthrough first-in-class human monoclonal antibody that binds to the Type I Interferon Receptor Subunit 1 (IFNAR1), blocking the downstream signaling of all Type I interferons (IFN-alpha, IFN-beta, IFN-omega, and IFN-kappa). Because cutaneous lupus lesions exhibit a profound Type I interferon gene expression signature, anifrolumab demonstrates exceptional, rapid cutaneous clearance in clinical trials (TULIP-1, TULIP-2) and is approved in the EU as add-on therapy for moderate-to-severe, active, autoantibody-positive SLE despite standard therapy; the label does not specify cutaneous disease.